Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

@article{Logunov2020SafetyAI,
  title={Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia},
  author={D. Logunov and I. V. Dolzhikova and O. V. Zubkova and Amir I Tukhvatullin and D. Shcheblyakov and A. Dzharullaeva and D. M. Grousova and A. Erokhova and A. V. Kovyrshina and A. G. Botikov and F. M. Izhaeva and O. Popova and T. A. Ozharovskaya and I. Esmagambetov and I. Favorskaya and Denis I Zrelkin and Daria V Voronina and Dmitry N Shcherbinin and A. S. Semikhin and Y. V. Simakova and E. A. Tokarskaya and N. L. Lubenets and D. A. Egorova and Maksim M Shmarov and N. Nikitenko and L. Morozova and E. Smolyarchuk and E. Kryukov and V. F. Babira and S. Borisevich and B. Naroditsky and A. Gintsburg},
  journal={Lancet (London, England)},
  year={2020},
  volume={396},
  pages={887 - 897}
}
  • D. Logunov, I. V. Dolzhikova, +29 authors A. Gintsburg
  • Published 2020
  • Medicine
  • Lancet (London, England)
  • Background We developed a heterologous COVID-19 vaccine consisting of two components, a recombinant adenovirus type 26 (rAd26) vector and a recombinant adenovirus type 5 (rAd5) vector, both carrying the gene for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein (rAd26-S and rAd5-S). We aimed to assess the safety and immunogenicity of two formulations (frozen and lyophilised) of this vaccine. Methods We did two open, non-randomised phase 1/2 studies at two… CONTINUE READING
    29 Citations

    Figures and Tables from this paper.

    SARS-CoV-2 vaccines in development
    • 30
    • PDF
    A systematic review of SARS-CoV-2 vaccine candidates
    • 5
    • PDF
    Vaccines for COVID‐19
    • 4
    Learning from the past: development of safe and effective COVID-19 vaccines
    The immunology of SARS-CoV-2 infections and vaccines

    References

    SHOWING 1-10 OF 39 REFERENCES
    An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
    • 228
    • PDF
    Virus-Vectored Ebola Vaccines
    • 7
    • PDF
    Methods and clinical development of adenovirus-vectored vaccines against mucosal pathogens
    • 32
    Adenoviruses as vaccine vectors
    • 440